Bone/Mineral Metabolism News

The FDA granted accelerated approval to vosoritide injection to improve growth among children aged 5 years or older with achondroplasia and open epiphyses.

Early identification and timely intervention are key to treating children with glucocorticoid-induced osteoporosis, a preventive strategy outlined in five important principles by a speaker at ACR Convergence 2021.

Avoiding the sun and practicing sun-protective behaviors does not show an association with osteoporotic fractures or reduced bone density, according to a study.

Women with a bone mineral density greater than 1.085 g/cm2 may have less risk for cardiovascular disease than those with a lower BMD, according to study data published in Nutrition, Metabolism & Cardiovascular Diseases.

Romosozumab is associated with marked reductions in all vertebral fracture grades, and these are sustained after transition to antiresorptive agents, post hoc analyses from the FRAME and ARCH studies show.

Fracture and mortality risks for men aged 80 years or older have different profiles, and an assessment of both could help to inform osteoporosis drug treatment decisions, according to a speaker.

Variables added to adjust the Fracture Risk Assessment Tool for recent fractures overestimated risk in a cohort of older women from Canada, according to a speaker.

A menarche-centered model assessing age at peak bone mineral density suggests bone loss women may begin as soon as 5 years after menarche, even among athletes, according to an analysis of longitudinal data.

Vitamin D3 supplementation did not reduce fracture risk in a large cohort of U.S. adults not selected for vitamin D deficiency or osteoporosis, according to an ancillary analysis of the VITAL trial.

Postmenopausal women with low bone mass saw greater gains in spine bone mineral density and less bone turnover when assigned monthly risedronate therapy compared with a 12-month regimen of impact and resistance exercises, study data show.